Metabolize raises $3.2M to turn Stanford research into post-GLP-1 products
What's the deal? MetabolizeDealroom has a profile for this one. Try Dealroom →, a San Francisco consumer health company, has raised $3.2 million in seed funding to commercialise products built on Stanford MedicineDealroom has a profile for this one. Try Dealroom →-originated research. AstanorDealroom has a profile for this one. Try Dealroom → led the round, with participation from Maia VenturesDealroom has a profile for this one. Try Dealroom →, LongGameDealroom has a profile for this one. Try Dealroom → Venture, and SOSV.
What's the endgame? Founded in 2024 by Morris Laster and Gideon Meir, Metabolize holds an exclusive license to Stanford intellectual property covering naturally occurring compounds identified by Jonathan Long, associate professor of pathology at Stanford Medicine. It calls the resulting approach Precision Metabolite Technology. The funding will support product development, validation, and manufacturing.
Why now? The company is targeting people moving off GLP-1 weight-loss drugs. Its first product, NATLEAN, is due to launch in January 2027 and is designed to help users taper off GLP-1 therapies by reducing food noise and supporting appetite regulation.
What could go wrong? The products sit in the consumer health category rather than regulated pharmaceuticals, so claims will rest on the strength of the underlying research. NATLEAN is still months from launch, and the broader portfolio remains in development.
"GLP-1 therapies have fundamentally changed the landscape of weight management and metabolic health, but they haven't solved every challenge," said Laster, chief executive officer of Metabolize. He pointed to a "large and growing population" cycling off treatment or not eligible for GLP-1s.
The signal: As GLP-1 drugs reshape weight management, investors are backing companies building adjacent markets for people after treatment. At $3.2 million, Metabolize's seed sits in the upper tier of rounds in our dataset, a sign of appetite for science-backed plays on the metabolic health wave.
Read more: pr.southjordanjournal.com
Image credit: Generated with Gemini
